Genomic landscape and clinical characteristics of patients (pts) with neuroendocrine prostate cancer (NEPC) with or without aggressive variant prostate cancer characterized by molecular signature (AVPC-MS).
Hedyeh Ebrahimi(City of Hope), Alex Chehrazi‐Raffle(City of Hope), Miguel Zugman(City of Hope), Benjamin Mercier(City of Hope), Luís Meza(City of Hope), Charles B. Nguyen(Michigan Medicine), Regina Barragán-Carrillo(Instituto Nacional de Cancerología), Sumanta Kumar Pal(City of Hope), Daniela V. Castro(City of Hope), Joann Hsu(City of Hope), Nazlı Dizman(City Of Hope National Medical Center), Tanya B. Dorff(City Of Hope National Medical Center), Salvador Jaime‐Casas(City of Hope), Xiaochen Li(Philippine Women's University), Koral Shah(City of Hope), Zeynep Büşra Zengin(City of Hope), Abhishek Tripathi(City of Hope), Peter D. Zang(City of Hope)
Cited by 1
Related Papers
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
|Journal of Allergy and Clinical Immunology|2020|2.4k
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
|Nature Medicine|2022|453
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
|PubMed|2022|172
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
|Cancer Discovery|2024|137
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma
|Cancer Immunology Research|2018|136